Sosei Heptares forms new neurological companies

4 February 2019

Japanese biotech Sosei Heptares Group (TYO: 4565) has announced an agreement with Medicxi, a venture fund dedicated to financing asset-centric firms, to form two independent companies, Orexia and Inexia.

The companies will aim to develop new therapies based on positive modulators of the G protein-coupled receptors, Orexin OX1 and OX2, for neurological diseases. Medicxi will be investing in both start-ups with an aggregate amount of up to 40 million euros ($46 million).

Orexia and Inexia will obtain a portfolio of related patents from Sosei and have the rights to exploit a series of Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, designed and developed by the Tokyo-based company, as well as access to proprietary know-how and development capabilities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK